Aptose Biosciences Inc.
Today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed ...
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Earnings call transcript: Immunomedics Q4 2023 sees stable cash flow
Inc. (Market cap: $34.46M) has reported its financial performance for the fourth quarter of 2023, highlighting a steady cash flow and strategic advancements in its clinical pipeline. According to ...
Stocks in play: Aptose Biosciences Inc.
Today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose’s Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in ...
Aptose Biosciences' leukemia drug shows early promise
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...